Indegene and Microsoft have announced a strategic collaboration to help life sciences companies scale up the adoption of purpose-built, enterprise-grade Generative AI (GenAI) services, aiming to drive faster innovation and business impact.
Key points:
- The partnership focuses on developing specialized medical and technology tools for GenAI services across commercial, medical, regulatory, and clinical functions.
- Indegene has already piloted nearly 50 real-world use cases of GenAI in the life sciences sector.
- The collaboration will initially focus on key areas including a Content Super App, future-ready medical content value chain, and data management and analytics for clinical trials.
Market estimate: According to a Microsoft-commissioned study by IDC, 79% of healthcare organizations have now embraced AI, indicating significant market penetration and potential for growth in the life sciences industry.
________________________________
Revolutionizing Life Sciences with AI
Indegene and Microsoft‘s (NASDAQ: MSFT) new partnership aims to transform the life sciences industry through the power of Generative AI. This collaboration comes at a crucial time when AI adoption in healthcare is rapidly accelerating.
Specialized Solutions for Life Sciences
The partnership will focus on developing tailored GenAI solutions for various aspects of the life sciences industry. These include a Content Super App for streamlined content creation and management, a future-ready medical content value chain, and advanced data management tools for clinical trials.
Empowering the Workforce
As part of this initiative, Indegene has launched ‘GenAI @ Work’, a program to train its 5,000+ employees in various aspects of GenAI. This move aims to enhance automation and productivity, allowing employees to focus on higher-value tasks.
Future Outlook
With 20 of the world’s top 20 biopharma companies among Indegene’s clients, this collaboration has the potential to significantly impact the life sciences industry. As GenAI continues to evolve, partnerships like this will be crucial in driving innovation and improving healthcare outcomes globally.
Source: Globenewswire
